Physician profile

Razak Dosani

Pulmonary Disease · Fort Myers, FL

NPI 1699832949

$1,402.27

in general payments reported to CMS, 2019-2025

24 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Glaxosmithkline, LLC. $279.64 2019-2020
Allergan, INC. $203.99 2019-2020
Astrazeneca Pharmaceuticals LP $162.63 2019-2022
Actelion Pharmaceuticals US, INC. $150.81 2019-2020
Mallinckrodt Enterprises LLC $68.77 2019
Boehringer Ingelheim Pharmaceuticals, INC. $62.18 2019-2020
Insmed, INC. $54.05 2019-2020
Sunovion Pharmaceuticals INC. $44.80 2019
Philips North America LLC $44.33 2019
Electromed, INC. $35.17 2019
Paratek Pharmaceuticals, INC. $32.01 2019
Janssen Pharmaceuticals, INC $28.85 2019-2020
Advanced Respiratory, INC $28.75 2019
Stryker Corporation $23.88 2021
Mylan Specialty L.P. $23.48 2019
Show all 24 companies

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Razak Dosani

$1,402.27

in general payments reported 2019-2025

Years
2019-2022
Top company
Glaxosmithkline, LLC.

https://glasscript.com/doctor/212294/razak-dosani

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.